Otonomy Completes Enrollment in Phase 2 Clinical Trial of OTO-313 in Tinnitus
22 févr. 2022 07h30 HE
|
Otonomy, Inc.
OTO-313 Phase 2 trial is fully enrolled ahead of scheduleTop-line results for all timepoints expected in mid-2022 SAN DIEGO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a...
Otonomy to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update
17 févr. 2022 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy Reports Corporate and Product Pipeline Update
06 janv. 2022 07h51 HE
|
Otonomy, Inc.
Multiple clinical trial readouts for OTO-313 in tinnitus and OTO-413 in hearing loss expected during 2022 Current capital funds operations into second half of 2023 SAN DIEGO, Jan. 06, 2022 (GLOBE...
Otonomy to Participate in the H.C. Wainwright BioConnect Conference
03 janv. 2022 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its...
Worldwide Hearing Aid Industry to 2026 - Featuring Sonova Holding, Demant and Starkey Among Others
25 nov. 2021 09h28 HE
|
Research and Markets
Dublin, Nov. 25, 2021 (GLOBE NEWSWIRE) -- The "Global Hearing Aid Market (2021 Edition) - Analysis By Hearing Devices (BTE, ITE, RIC, ITC and CIC), Type of Hearing Loss, Technology, Patient Type, By...
Otonomy Reports Third Quarter 2021 Financial Results and Provides Corporate Update
10 nov. 2021 16h18 HE
|
Otonomy, Inc.
OTO-313 Phase 2 trial in tinnitus ongoing with results expected in mid-2022Enrollment nearly complete in OTO-413 Phase 2a cohort in hearing loss with results moved forward to early in second quarter...
Otonomy to Report Third Quarter 2021 Financial Results and Provide Corporate Update
03 nov. 2021 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy Announces Multiple Presentations at Neuroscience 2021 Meeting
27 oct. 2021 07h30 HE
|
Otonomy, Inc.
Presentation of positive top-line clinical results for OTO-313 in tinnitus and OTO-413 in hearing loss Supportive preclinical data to be presented for OTO-825 gene therapy and OTO-510 otoprotection...
Otonomy Announces Publication of Phase 1/2 Trial Results Showing Tinnitus Improvement in Patients Receiving OTO-313
12 oct. 2021 07h30 HE
|
Otonomy, Inc.
Results published in Otology & Neurotology, a leading journal in fieldOTO-313 was well-tolerated and demonstrated a statistically significant higher proportion of responders than placebo across...
InnerScope Hearing Technologies (OTC: INND) to Participate in the Virtual Home Health & Diabetes Care Program, Sept. 20–23, 2021
20 sept. 2021 08h00 HE
|
InnerScope Hearing Technologies, Inc.
ROSEVILLE, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- InnerScope Hearing Technologies Inc. (OTC: INND) ("InnerScope" or the “Company”), an emerging and disruptive leader in the...